|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||143.05 - 146.68|
|52 Week Range||134.25 - 178.86|
|PE Ratio (TTM)||6.41|
|Earnings Date||May 16, 2018 - May 21, 2018|
|Forward Dividend & Yield||1.36 (0.93%)|
|1y Target Est||175.13|
Among the companies with shares expected to trade actively in Thursday's session are Apple, General Motors, General Electric, 21st Century Fox, Qualcomm and Best Buy.
The electronics retailer earned an adjusted 82 cents per share for the first quarter , 8 cents a share above estimates, with revenue also exceeding forecasts. Best Buy reported a comparable store sales increase of 7.1 percent, well above the consensus Thomson Reuters forecast of a 3.0 percent increase. Medtronic MDT – The medical device maker's quarterly numbers came in 3 cents above estimates at an adjusted $1.42 per share, with revenue also above Street forecasts.
On a per-share basis, the San Francisco-based company said it had a loss of $5.58. Earnings, adjusted for one-time gains and costs, came to $3.49 per share. The results fell short of Wall Street expectations. ...
Medical supplies distributor McKesson Corp. said Thursday it had a net loss of $1.146 billion, or $5.58 a share, in its fiscal fourth quarter to March 31, after a profit of $3.588 billion, or $16.76 a share, in the year-earlier period. The loss was driven primarily by non-cash goodwill and long-lived asset impairment charges in the company's European and Canadian retail businesses, which were partially offset by benefits related to the December tax revamp.
McKesson Corporation today reported that revenues for the fourth quarter ended March 31, 2018, were $51.6 billion, up 6% compared to $48.7 billion a year ago. On a constant currency basis, revenues increased 4% over the prior year.
Retail earnings will continue on Thursday with Best Buy and The Gap reporting results as volumes remain light ahead of the holiday weekend in the U.S.
The FDA released a list of drugmakers it said are getting in the way of generic drug development. Stocks of pharmacy benefit managers and biotech companies still outperformed the market. The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president's blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.
McKesson's (MCK) Q4 results likely to be driven by core segmental performance; solid view and new growth initiatives buoy optimism.
The decision to sue is seen as an acknowledgment opioid makers won’t get serious about settling until the cases go to trial.
Some McKesson Corp. directors must face an investor lawsuit accusing them of failing to honor promises to ensure internal systems for spotting suspicious opioid shipments functioned properly. Two shareholders of the San Francisco-based company can press claims the distributor’s board was asleep at the switch when it came to overseeing such shipments after a 2008 settlement spawned by the firm’s inept monitoring of the painkillers, a federal judge in Oakland, California, ruled. The suit raises legitimate questions about whether directors ignored “multiple red flags” about opioid shipments even after agreeing to step up compliance oversight as a result of a deal with the government, U.S. District Court Judge Claudia Wilken wrote in a May 14 order.
NEW YORK, May 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE ...
WASHINGTON—Prescription-drug wholesalers that for years shipped hundreds of opioid pills per person to small towns in West Virginia mostly denied they were a cause of surging addiction as lawmakers grilled them on Tuesday. Most company executives told a House hearing that their companies’ actions didn’t fan the opioid epidemic in the state. Only one executive, Joseph Mastandrea, chairman of Miami-Luken Inc. said that his company had a “shared responsibility” for the opioid crisis.
and H.D. Smith Wholesale Drug Company told the House Committee on Energy and Commerce their companies did not contribute to the opioids epidemic. The five drug distribution companies were ordered to appear before the committee on Tuesday, May 8. Since last May the committee has been investigating the number of opioid pills that were shipped to West Virginia.
George Barrett, executive chairman and past CEO of Cardinal Health Inc., apologized before a Congressional committee investigating the role of drug distributors in sending millions of doses of opioids to questionable pharmacies, particularly two in rural West Virginia. Barrett explained today's procedures would have blocked the shipments.
President Donald Trump is expected to outline new policies to deliver on his pledge to bring prices down in a speech that could come this week.
McKesson Corporation (MCK) today announced that its Board of Directors has elected Brad Lerman as a new independent director, effective April 24, 2018. With the election of Mr. Lerman, the size of McKesson’s Board of Directors increases from eight to nine members, eight of whom are independent. “With more than 25 years of experience bringing insights that bridge compliance and government relations with corporate strategy, Brad will be an immediate asset to McKesson’s Board of Directors,” said John H. Hammergren, chairman and chief executive officer, McKesson.
McKesson Corporation will release financial results for its fourth fiscal quarter ended March 31, 2018 on Thursday, May 24, 2018, prior to the opening of trading on the New York Stock Exchange.